Pipazetate

Pipazetate
Clinical data
Trade namesDipect, Lenopect, Selvignon, Selvigon, Theratuss, Toraxan
Other namesPipazethate; D-254; LG-254; SKF-70230A; SQ-15874
AHFS/Drugs.comInternational Drug Names
ATC code
Identifiers
IUPAC name
  • 2-(2-piperidin-1-ylethoxy)ethyl 10H-pyrido[3,2-b][1,4]benzothiazine-10-carboxylate
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
KEGG
CompTox Dashboard (EPA)
ECHA InfoCard100.016.826
Edit this at Wikidata
Chemical and physical data
FormulaC21H25N3O3S
Molar mass399.51 g·mol−1
3D model (JSmol)
SMILES
  • O=C(OCCOCCN1CCCCC1)N3c4c(Sc2c3nccc2)cccc4
InChI
  • InChI=1S/C21H25N3O3S/c25-21(27-16-15-26-14-13-23-11-4-1-5-12-23)24-17-7-2-3-8-18(17)28-19-9-6-10-22-20(19)24/h2-3,6-10H,1,4-5,11-16H2 checkY
  • Key:DTVJXCOMJLLMAK-UHFFFAOYSA-N checkY
  (verify)

Pipazetate (INN) (brand names Dipect, Lenopect, Selvigon, Theratuss, Toraxan), or pipazethate (USAN), is a pyridobenzthiazine cough suppressant, closely related to the phenothiazine class.[1][2] It binds to the sigma-1 receptor with an IC50 value of 190 nM.[3] It also has local anesthetic action, and in large doses can produce seizures.[4]

As the brand name Theratuss, it was approved by the FDA in 1962, on evidence of safety only. It was withdrawn from the US market in 1972 when the manufacturer, E.R. Squibb and Sons, failed to produce evidence of efficacy.[5] Clinical studies showed that it did not decrease cough frequency at recommended dosages.[6]

Side effects, which are infrequent, include nausea, vomiting, drowsiness, fatigue, rash, and tachycardia.[6]

References

  1. ↑ Elks J (14 November 2014). The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. Springer. pp. 985–. ISBN 978-1-4757-2085-3.
  2. ↑ Index Nominum 2000: International Drug Directory. Taylor & Francis. 2000. pp. 1418–. ISBN 978-3-88763-075-1.
  3. ↑ Klein M, Musacchio JM (October 10, 1988). "Dextromethorphan binding sites in the guinea pig brain". Cellular and Molecular Neurobiology. 8 (2): 149–156. doi:10.1007/BF00711241. PMID 3044591. S2CID 33844132.
  4. ↑ Martín, Alfonso Velasco (2004). "Tratamiento sintomático de la tos y del resfriado común". Farmacología clínica y terapéutica médica. p. 259. ISBN 9788448604271.
  5. ↑ Certain Preparations Containing Dihyprylone or Pipazethate Hydrochloride; Notice of Withdrawal of Approval of New-Drug Applications (PDF). Federal Register (Report). Vol. 37. August 5, 1972. p. 15887. FDC–D–458.
  6. 1 2 Council on Drugs (1971). AMA Drug Evaluations (Report). Chicago: American Medical Association. p. 360–3. LCCN 75147249. Retrieved April 5, 2021.



This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.